Sage Therapeutics Inc Expected To Post A Loss Of $1.02 A Share: Earnings Preview

Sage Therapeutics

25/04/2025 22:32

SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports  results on April 29 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 77.9% increase in revenue to $14.056 million from $7.9 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.

​LSEG's mean analyst estimate for SAGE Therapeutics Inc is for a loss of $1.02 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 15 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.8% in the last three months. ​

Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.00​, above​ its last closing price of $7.79. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.52
-1.51
-1.56
Missed
-3.6
Sep. 30 2024
-1.53
-1.53
-1.53
Met
0.2
Jun. 30 2024
-1.70
-1.66
-1.70
Missed
-2.5​
Mar. 31 2024
-1.64
-1.65
-1.80
Missed
-9.3
​​Dec. 31 2023
-1.65
-1.28
-1.80
Missed
-40.9
Sep. 30 2023
-2.76
-2.73
-3.37
Missed
-23.4​
Jun. 30 2023
-2.56
-2.55
-2.68
Missed
-4.9
Mar. 31 2023
-2.47
-2.50
-2.46
Beat
1.4

This summary was machine generated April 25 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)